In short: Mounjaro and hair loss<\/p>\n
Yes, Mounjaro can trigger hair loss, but not through any direct damage from the drug itself. The culprit is rapid weight loss, which sets off telogen effluvium, a diffuse and almost always reversible type of shedding. At the lower diabetes dose the risk is small; when used for weight loss at high doses it sits at around 5%.<\/p>\n
- \n
- Cause:<\/strong> not the drug, but rapid weight loss. In the weight-loss trials around 4.9 to 5% of people were affected versus around 1% on placebo, and the MHRA classes alopecia as common (up to 1 in 10).<\/li>\n
- Temporary and reversible:<\/strong> the follicles stay intact, and most people recover even without stopping treatment.<\/li>\n
- Regrowth:<\/strong> typically visible after 6 to 12 months, once your weight and nutrient levels have settled. Women are affected more than men (7.1% vs 0.5%).<\/li>\n
- When to see a doctor:<\/strong> if you notice bald patches, an irritated scalp, or a clear pattern that remains after 12 months.<\/li>\n<\/ul>\n<\/div>\n\n\n\n
Thousands of patients in the UK are asking themselves this very question, now that Mounjaro is no longer just a diabetes medicine but is also prescribed for weight loss on the NHS. Because tirzepatide is already used so widely for weight management here, the most reliable new data on Mounjaro and hair loss come from the UK itself. The same drug, the same mechanism, so the findings apply to everyone taking it.<\/p>\n\n\n\n
The short answer is this: yes, hair loss does happen on Mounjaro, but almost never in the way most people assume. The active ingredient, tirzepatide, does not attack the hair root directly. The culprit is the rapid weight loss itself, which triggers a temporary type of shedding called telogen effluvium. That is the crucial distinction: telogen effluvium is almost always reversible. In this article we go through the evidence on Mounjaro, put the figures from the licensing trials and the UK MHRA register into context, and tell you exactly what you can do about the shedding and when to take a closer look.<\/p>\n\n\n\n
If your hair loss appears while you are on Mounjaro, the most likely explanation is the pace of your weight loss, not permanent damage. So do not stop the injections in a panic; get the situation assessed instead. When in doubt, a professional opinion is worth having before you change anything about your treatment.<\/p>\n\n\n\n
Does Mounjaro cause hair loss? What the studies show<\/h2>\n\n\n\n
![\"Bar](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/stats_mounjaro_uk.webp\")
Hair loss reported in SURMOUNT-1 by dose: placebo 0.9%, 5 mg 5.1%, 10 mg 5.3%, 15 mg 4.9%.<\/figcaption><\/figure>\n\n\n\n The most robust figures come from the weight-loss licensing trials. In the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022 with 2,539 participants, hair loss was reported by 5.1% (5 mg), 5.3% (10 mg) and 4.9% (15 mg) of tirzepatide patients depending on the dose, compared with just 0.9% in the placebo group. That is a roughly fivefold increase in relative risk, but in absolute terms it still affects only a minority of those treated.<\/p>\n\n\n\n
For the UK the official product document is what counts. The UK SmPC for Mounjaro uses clear wording in section 4.8: hair loss was reported in 4.9% of patients treated with tirzepatide and in 1.0% on placebo. The events were mostly mild, the majority recovered while continuing treatment, and not a single patient stopped therapy because of the hair loss. The medicines regulator, the MHRA, therefore classes alopecia as “common”, meaning at least 1 in 100 but fewer than 1 in 10 of those treated.<\/p>\n\n\n\n
![\"Scalp](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/te_vs_aga_uk.webp\")
Diffuse telogen effluvium (thinner all over) versus patterned androgenetic alopecia (hairline and crown).<\/figcaption><\/figure>\n\n\n\n An important point for understanding Mounjaro: these figures come from the weight-loss trials at the high doses. In the original diabetes trials (the SURPASS series) alopecia did not show up as a notable side effect at all, because weight loss there is far smaller. It was not until February 2025 that the US regulator, the FDA, added hair loss retrospectively to the post-marketing observations section of the US Mounjaro label. That underlines the point: the risk is tied to the degree of weight loss, not to the drug itself. You can read more about the shared active ingredient and how both brands work in our hub article on tirzepatide and hair loss<\/a>.<\/p>\n\n\n\n
The pharmacovigilance data paint a more nuanced picture too. A FAERS analysis by Godfrey and colleagues (JEADV 2025) found a significantly raised reporting signal for alopecia with tirzepatide (ROR 1.73), although lower than for semaglutide (ROR 2.46). A later, adjusted analysis by Lee and Kim (2026) found no significant signal at all for tirzepatide. Variation like this stems from different analytical models and observation periods, and it is a reminder to be cautious about individual spontaneous-reporting figures.<\/p>\n\n\n\n
\n - Temporary and reversible:<\/strong> the follicles stay intact, and most people recover even without stopping treatment.<\/li>\n
![\"Infographic:](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/mechanism_uk.webp\")
![\"Timeline](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/timeline_uk.webp\")